Advertisement

Vasopressin pp 549-578 | Cite as

Vasopressin and Human Behavior

  • Jellemer Jolles

Abstract

Peptides related to the pituitary hormone vasopressin (VP) have been found to influence aspects of memory processes and learning in laboratory animals (De Wied, 1969; see De Wied, 1983, for review). This finding has led to the suggestion that VP might have a clinical application in the treatment of human memory disorders. Unfortunately, it is not simple to state whether VP has been found effective. This is because clinical studies differ with respect to the nature of the patient population (e.g., brain trauma, alcoholism, depression) and the methods of testing used. In addition, there is wide variation in pharmacological parameters, such as the dose, route, and frequency of peptide administration. Accordingly, some studies report positive effects of VP administration, whereas others are negative (Jolles, 1983b).

Keywords

Memory Process Senile Dementia Heroin Addict Memory Disorder Korsakoff Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson, L. T., David, R., Bonnet, R., and Dancis, J., 1979, Passive avoidance learning in Lesch-Nyhan disease: Effect of l-desamino-8-arginine-vasopressin, Life Sci. 24: 905–910.PubMedGoogle Scholar
  2. Ang, V. T. Y., and Jenkins, J. S., 1982, Blood CSF barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog, J. Endocrinol. 93: 319–325.PubMedGoogle Scholar
  3. Beckwith, B. E., Petros, T., Kanaan-Beckwith, S., Couk, D. I., and Haug, R. J., 1982, Vasopressin analog (DDAVP) facilitates concept learning in human males, Peptides 3: 627–630.PubMedGoogle Scholar
  4. Beckwith, B. E., Couk, D. I., and Till, T. S., 1983, Vaspressin analog influences the performance of males on a reaction time task, Peptides 4: 707–709.PubMedGoogle Scholar
  5. Beckwith, B. E., Till, R. E., and Schneider, V., 1984, Vasopressin analog (DDAVP) improves memory in human males, Peptides 5: 819–822.PubMedGoogle Scholar
  6. Blake, D. R., Dodd, M. J., and Grimley Evans, J., 1978, Vasopressin in amnesia, Lancet 1: 608.PubMedGoogle Scholar
  7. Branconnier, R. J., 1983, Computerized psychometrics, in: Assessment in Geriatric Psychopharmacology (T. Crook, S. Ferris, and R. Bartus, eds.), pp. 203–213, Mark Powley Association, New Canaan, Connecticut.Google Scholar
  8. Brand, N., and Jolies, J., 1985, Learning and retrieval rate of words presented auditorially and visually, J. Gen. Psychol 112: 210–210.Google Scholar
  9. Brand, N., and Jolies, J., 1987, Information processing in depression and anxiety, Psychol. Med. 17: 145–154.PubMedGoogle Scholar
  10. Buijs, R. M., 1978, Intra-and extrahypothalamic vasopressin and oxytocin pathways in the rat: Pathways to the limbic system, medulla oblongata and spinal cord, Cell Tissue Res. 192: 423–435.PubMedGoogle Scholar
  11. Butters, N., 1985, Alcoholic Korsakoff s syndrome: Some unresolved issues, concerning etiology, neuropathology and cognitive defects. J. Exp. Clin. Neuropsychol. 7: 101–210.Google Scholar
  12. Calandra, C., Drago, F., and Filetti, S., 1980, Su un caso con turbe mnestische trattato con vasopressina, Min. Psychiat. 21: 63–66.Google Scholar
  13. Christensen, A. L., 1975, Luria’s Neuropsychological Investigation, Munksgaard, Copenhagen.Google Scholar
  14. Couk, D. I., and Beckwith, B. E., 1982, Effects of desmopressin acetate (DDAVP) on the learning of a brightness discrimination, Peptides 3: 521–526.PubMedGoogle Scholar
  15. Delwaide, P. J., Devoitille, J. M., and Ylieff, M., 1980, Acute effects of drugs upon memory of patients with senile dementia, Acta Psychiatrica Belg. 80: 748–754.Google Scholar
  16. De Wied, D., 1969, Effects of peptide hormones on behavior, in: Frontiers in Neuroendocrinology (W. F. Ganong and L. Martini, eds.), pp. 97–140, Oxford University Press, London.Google Scholar
  17. De Wied, D., 1971, Longterm effect of vasopressin on the maintenance of a conditioned avoidance response in rats, Nature (Lond.) 232: 58–60.Google Scholar
  18. De Wied, D., 1976, Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments, Life Sci. 19: 685–690.PubMedGoogle Scholar
  19. De Wied, D., 1983, Central actions of neurohypophysial hormones, Prog. Brain Res. 60: 155–169.PubMedGoogle Scholar
  20. De Wied, D., 1984, The importance of vasopressin in memory, Trends Neurosci 7: 62–63.Google Scholar
  21. De Wied, D., and Jolies, J., 1983, Neuropeptides derived from pro-opiomelanocortin: Behavioral, physiological and neurochemical effects, Physiol. Rev. 62: 976–1059.Google Scholar
  22. De Wied, D., Gaffon, O., Van Ree, J. M., and De Jong, W., 1984, Nature (Lond.) 308: 276–278.Google Scholar
  23. Dimond, S., 1980, Neuropsychology, Butterworths, London.Google Scholar
  24. Drago, F., Rapisarda, V., Calandra, A., Filetti, S., and Scapagnini, U., 1981, A clinical evaluation of vasopressin effects on memory disorders, Acta Ther. 7: 345–352.Google Scholar
  25. Durso, R., Fedio, P., Brouwers, P., Cox, C., Martin, A. J., Ruggieri, S. A., Tamminga, C. A., and Chase, T. N., 1982, Lysine vasopressin in Alzheimer’s disease. Neurology (NY.) 32: 674–677.Google Scholar
  26. Eisenberg, J., Chazon-Gologorsky, S., Hattab, J., and Belmaker, R.M., 1984, A controlled trial of vasopressin treatment in childhood learning disorder, Biol Psychiatry 19: 1137–1141.PubMedGoogle Scholar
  27. Eisenberg, J., Hamburger-Bar, A., and Belmaker, R. H., 1984, The effect of vasopressin treatment on learning in Down’s syndrome, J. Neural Transm. 60: 143–147.PubMedGoogle Scholar
  28. Fehm-Wolfsdorf, G., Born, J., Voigt, K-H., and Fehm, H-L., 1984, Human memory and neurohypophyseal hormones: Opposite effects of vasopressin and oxytocin, Psychoneuroendocrinology 9: 285–292.PubMedGoogle Scholar
  29. Fehm-Wolfsdorf, G., Born, J., Elbert, Th., Voigt, K-H., and Fehm, L. H., 1985, Vasopressin does not enhance memory processes: A study in human twins, Peptides 6: 297–300.PubMedGoogle Scholar
  30. Ferris, S. H., 1983, Neuropeptides in the treatment of Alzheimer’s disease, in: Alzheimer’s disease (B. Reisberg, ed.), pp. 369–373, Free Press/Macmillan, New York.Google Scholar
  31. Fewtrell, W. D., House, A. O., Jamie, P. F., Oates, M. R., and Cooper, J. E., 1982, Effects of vasopressin on memory and new learning in a brain-injured population, Psychol. Med. 12: 423–425.PubMedGoogle Scholar
  32. Forisz, L., 1952a, Treatment of mental patients with antidiuretic hormone of the posterior pituitary, Dis. Nerv. Syst. 13: 42–44.Google Scholar
  33. Forisz, L., 1952b, The use of Pitressin in the treatment of schizophrenia with deterioration, N. C. Med. J. 13: 76–80.Google Scholar
  34. Fraenkel, H. M., van Beek-Verbeek, G., Fabriek, A. J., and van Ree, J. M., 1983, Desglycinamide9-Arginine8-Vasopressin and ambulant methadone-detoxificaiton of heroin addicts, Alcohol Alcoholism 18: 331–335.Google Scholar
  35. Franceschi, M., Tancredi, O., Savio, G., and Smirne, S., 1982, Vasopressin and physostigmine in the treatment of amnesia, Eur. Neurol. 21: 388–391.PubMedGoogle Scholar
  36. Frolkis, V. V., Golovchenko, S. F., Medved, V. I., and Frolkis, R. A., 1982, Vasopressin and cardiovascular system in aging, Gerontology 28: 290–302.PubMedGoogle Scholar
  37. Gash, D. M., and Thomas, G. T., 1983, What is the importance of vasopressin in memory processes?, Trends Neurosci. 6: 197–198.Google Scholar
  38. Gash, D. M., and Thomas, G. T., 1984, The importance of vasopressin in memory:Reply, Trends Neurosci. 7: 64–65.Google Scholar
  39. Gilot, P., Crabbe, J., and Legros, J. J., 1980, Bilan mnésique de cinq sujects présentant un diabète central idiopathique familiar, Acta Psychiatrica Belg. 80: 755–761.Google Scholar
  40. Gold, P. E., and Van Buskirk, A., 1976, Effects of posttrial hormone injections on memory processes, Horm.Behav. 7: 509–517.PubMedGoogle Scholar
  41. Gold, P. W., Ballenger, J. C., Weingartner, H., Goodwin, F. K., and Post, R. M., 1979, Effects of l-desamino-8-D-arginine vasopressin on behavior and cognition in primary affective disorders, Lancet. 1: 992–994.Google Scholar
  42. Gold, P. W., Robertson, G. L., Ballenger, J. C., Goodwin, F. K., Rubinow, D. R., Kellner, C., and Post, R. M., 1983, Neurohypophyseal function in affective illness, Psychopharmacol. Bull. 19: 426–431.PubMedGoogle Scholar
  43. Jenkins, J. S., Mather, H. M., and Coughlan, A. K., 1982, Effects of desmopressin in normal and impaired memory, J. Neurol. Neurosurg. Psychiatry 45: 830–831.PubMedGoogle Scholar
  44. Jenkins, J. S., Mather, H. M., Coughlan, A. K., and Jenkins, D. G., 1979, Desmopressin in posttraumatic amnesia, Lancet 1245–1246.Google Scholar
  45. Jenkins, J. S., Mather, H. M., Coughlan, A. K., and Jenkins, D. G., 1981, Desmopressin and desglycinamide vasopressin in posttraumatic amnesia, Lancet 1: 39.PubMedGoogle Scholar
  46. Jennekens-Schinkel, A., Wintzen, A. R., and Lanser, J. B. K., 1985, A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man, Prog. Neuropsychopharmacol. and Biol Psychiatry 9: 273–284.Google Scholar
  47. Jensen, J. P. A., 1980, Vasopressin therapy in Parkinson’s disease, Acta Neurol. Scand. 62: 197–199.PubMedGoogle Scholar
  48. Jolies, J., 1983a, The pharmacology of memory, Int. Med. 3: 2–5.Google Scholar
  49. Jolies, J., 1983b, Vasopressin-like peptides and the treatment of memory disorders in man, Prog. Brain Res. 60: 169–182.Google Scholar
  50. Jolies, J., 1985, Early diagnosis of dementia: Possible contributions from neuropsychology, in: Aging of the Brain (W. H. Gispen and J. Traber, eds.), pp. 84–100, Springer-Verlag, Berlin.Google Scholar
  51. Jolies, J., 1986a, Neuropeptides and cognitive disorders, in: Psychiatric Disorders: Neurotransmitters and Neuropeptides (J. M. van Ree and J. Matthÿse, eds.), pp. 177–192, Elsevier, Amsterdam.Google Scholar
  52. Jolies, J., 1986b, Cognitive, emotional, and behavioral dysfunctions in aging and dementia, Prog. Brain Res. 70: 15–39.Google Scholar
  53. Jolies, J., and Hijman, R., 1983, The neuropsychology of aging and dementia, Dev. Neurol. 7: 277–250.Google Scholar
  54. Jolies, J., and Gaillard, A.W.K., A paper and pencil version of the Sternberg memory comparison task (Submitted for publication).Google Scholar
  55. Kirkland, J., Lye, M., Goddard, C., Vargast, E., and Davies, I., 1984, Plasma arginine vasopressin in dehydrated elderly patients, Clin. Endocrinol. 20: 451–456.Google Scholar
  56. Koch-Henriksen, N., and Nielson, H., 1981, Vasopressin in post-traumatic amnesia, Lancet 1: 38–39.PubMedGoogle Scholar
  57. Koizumi, H. M., Rowe, H., and Clark, R., 1981, Vasopressin (antidiuretic hormone) for postencephalitic memory loss: A pilot study, J. Clin. Psychiatry 42: 217.PubMedGoogle Scholar
  58. Korsgaard, S., Casey, D. E., Damgaard Pedersen, N. E., Jørgensen, A., and Gerlach, J., 1981, Vasopressin in anergic schizophrenia, Psychopharmacology 74: 379–382.PubMedGoogle Scholar
  59. Kovacs, G. L., Vecsei, L., Szabo, G., and Telegdy, G., 1977, The involvement of catecholaminergic mechanisms in the behavioral action of vasopressin, Neurosci, Lett. 5: 337–344.Google Scholar
  60. Kovacs, G. L., Bohus, B., and Versteeg, D. H. G., 1979, Facilitation of memory consolidation by vasopressin: Mediation by terminals of the dorsal noradrenergic bundle?, Brain Res. 172: 73–85.PubMedGoogle Scholar
  61. Kovacs, G. L., Vecsei, L., Medve, L., and Telegdy, G., 1980, Effect of the endogenous vasopressin content of the brain on memory processes: The role of catecholaminergic mechanisms, Exp. Brain Res. 38: 357–361.PubMedGoogle Scholar
  62. Kruse, H., Van Wimersma Greidanus, Tj. B., and De Wied, D., 1977, Barrel rotation induced by vasopressin and related peptides in rats, Pharmacol. Biochem. Behav. 7: 311–313.PubMedGoogle Scholar
  63. Láczi, F., Valkusz, Zs., Laszlo, F. A., Wagner, A., Jardanhazy, T., Szasz, A., Szilard, J., and Telegdy, G., 1982, Effects of lysine-vasopressin and 1-desamino-8-D-arginine-vasopressin on the memory in healthy individuals and diabetes insipidus patients, Psychoneuroendocrinology 7: 185–193.PubMedGoogle Scholar
  64. Láczi, R., Van Ree, J.M., Wagner, A., Valkusz, Zs., Jardanhazy, T., Kovacs, G. L., Telegdy, G., Szilard, J., Laszlo, F.A., and De Wied, D., 1983a, Effects of desglycinamide-arginine-vasopressin (DGAVP) on memory processes in diabetes insipidus patients and in non-diabetic subjects, Acta. Endocrinol. 102: 205–212.PubMedGoogle Scholar
  65. Láczi, F., Van Ree, J. M., Balogh, L., Szasz, A., Jardanhazy, T., Wagner, A., Gaspar, L., Valkusz, Zs., Dobranovics, I., Szilard, J., Laszlo, F.A., and De Wied, D., 1983b, Lack of effect of DGAVP on memory in patients with Korsakoff syndrome, Acta. Endocrinol. 104: 177–182.PubMedGoogle Scholar
  66. Legros, J. J., Gilot, P., Schmitz, S., Bruwier, M., Mantanus, H., and Timsit-Bertheir, M., 1980, Neurohypophyseal peptides and cognitive function: A clinical approach, in: Progress in Psychoneuroendocrinology (F. Brambilla, G. Racagni, D. De Wied, eds.), pp. 325–337, Elsevier, Amsterdam.Google Scholar
  67. Legros, J. J., and Lancranjan, I., 1984, Vasopressin in neuropsychiatric disorders, in: Psychoneuroendocrine Dysfunction (N. S. Shah and A. G. Donald, eds.), pp. 255–278, Plenum, New York.Google Scholar
  68. Legros, J. J., Gilot, P., Seron, X., Ciaessens, J., Adam, A., Moeglen, J.M., Audibert, A., and Berchier, P., 1978, Influence of vasopressin on learning and memory, Lancet 1: 41–42.PubMedGoogle Scholar
  69. Lerer, B., Zabow, T., Egnal, N., and Belmaker, R.H., 1983, Biol. Psychiat. 18: 821–824.PubMedGoogle Scholar
  70. Lezak, M. D., 1983, Neuropsychological Assessment, (2nd. ed.), Oxford University Press, New York.Google Scholar
  71. Lhermitte, F., and Signoret, J. L., 1972, Analyse neuropsychologique et diffèrentation des syndromes anmésiques, Rev. Neurol. 126: 161–178.PubMedGoogle Scholar
  72. Lishman, V. A., 1980, Head injury, in: Organic Psychiatry, 2nd. ed., pp. 191–262, Oxford, Blackwell Scientific, London.Google Scholar
  73. Luersson, T. G., and Robertson, G.L., 1980, Cerebrospinal fluid vasopressin and vasotocin in health, in: Neurobiology of Cerebrospinal Fluid (J. H. Wood, ed.), pp. 613–625, Plenum, New York.Google Scholar
  74. Luria, A. R., 1976, The Neuropsychology of Memory, Winston, Washington, D. C.Google Scholar
  75. Luria, A. R., 1980, Higher Cortical Functions in Man, 2nd ed., Basic Books, New York.Google Scholar
  76. McGeer, P. L., Eccles, J. C., and McGeer, E. G., 1978, Neuronal mechanisms in learning and memory, in: Molecular Neurobiology of he Mammalian Brain, (P. L. McGeer, J. C. Eccles, and E. G. McGeer, eds.), pp. 501–535, Plenum, New York.Google Scholar
  77. Medvedev, V. I., Bakharev, V. D., Grechko, A. T., and Nezovibat’ko, V. N., 1981, Effect of vasopressin and adrenocorticotrophic hormone fragment ACTH4−7 on human memory, Hum. Physiol. 6: 307–310.Google Scholar
  78. Nebes, R. D., Reynolds, C. F. III, and Horn, L. C., 1984, The effect of vasopressin on memory in the healthy elderly, Psychiat. Res. 11: 49–59.Google Scholar
  79. Newcombe, F., 1980, Memory: A neuropsychological approach, Trends Neurosci. 3: 179–182.Google Scholar
  80. O’Keefe, J., and Nadel, L., 1978, The Hippocampus as a Cognitive Map, Clarendon Press, Oxford.Google Scholar
  81. Oliveros, J. C., Jandali, M. K., Timsit-Berthier, M., Remy, R., Benghezal, A., Audibert, A., and Moeglen, J. M., 1978, Vasopressin in amnesia, Lancet 1: 42.PubMedGoogle Scholar
  82. Peabody, C. A., Thiemann, S., Pigache, R., Miller, T. P., Berger, Ph. A., Yesavage, J., and Tinklenberg, J. R., 1985, Desglycinamide-9-Arginine-8-Vasopressin(DGAVP, Organon 5667) in patients with dementia, Neurobiol. Aging 6: 95–100.PubMedGoogle Scholar
  83. Perlow, M. J., Reppert, S. M., Artman, M. A., Fisher, P. A., Luf, S. M., and Robinson, A. G., 1982, Oxytocin, vasopressin and estrogen-stimulated neurophysin: Daily patterns of concentration in cerebrospinal fluid, Science 216: 1416–1418.PubMedGoogle Scholar
  84. Posmurová, M., Alda, M., Plavka, R., Filip, V., and Karen, P., 1983, Single-dose effects of two vasopressin derivatives in healthy volunteers: A psychometric study, in: Neuropeptides and Psychosomatic Processes (E. Endroczi, L. Angelucci, K. Scapagnini, and D. De Wied, eds), pp. 73–80, Academiai Kiado, Budapest.Google Scholar
  85. Reichert, W. H., and Blass, J. P., 1982, A placebo-controlled trial shows no effect of vasopressin on recovery from closed head injury, Ann. Neurol. 12: 390–392.PubMedGoogle Scholar
  86. Reppert, S. M., Artman, H. G., Swaminathan, S., and Fisher, D. A., 1981, Vasopressin exhibits a rhythmic daily pattern in cerebrospinal fluid but not in blood, Science 213: 1256–1257.PubMedGoogle Scholar
  87. Reus, V. I., Silberman, E., Post, R. M., Weingartner, H., 1979, d-Amphetamine: Effects on memory in a depressed population, Biol. Psychiatry 13: 345–356.Google Scholar
  88. Russell, E. W., 1981, The pathology and clinical examination of memory, in: Handbook of Clinical Neuropsychology (S. B. Filskov and T. J. Boll, eds.), pp. 287–319, Wiley, New York.Google Scholar
  89. Schrier, R. W., Berl, T., and Anderson, R. J., 1979, Osmotic and nonosmotic control of vasopressin release, Am. J. Physiol. 236: F321–F329.PubMedGoogle Scholar
  90. Segal, M., and Bloom, F. E., 1976, The action of norepinephrine in the rat hippocampus. IV. The effects of locus coeruleus stimulation on evoked hippocampal unit activity, Brain. Res. 107: 513–525.PubMedGoogle Scholar
  91. Squire, L. R., and Davis, H. P., 1981, The pharmacology of memory: A neurobiological perspective, Annu. Rev. Pharmacol. Toxicol. 21: 323–356.PubMedGoogle Scholar
  92. Strupp, B., Weingartner, H., Goodwin, F. K., and Gold, P. W., 1983, Neurohypophyseal hormones and cognition, Pharmacol. Ther. 23: 267–279.PubMedGoogle Scholar
  93. Sulkava, R., and Amberla, K., 1981, Alzheimer’s disease and senile dementia of Alzheimer type: A neuropsychological study, Acta Neurol. Scand. 65: 541–552.Google Scholar
  94. Sundquist, J., Forsling, M. L., Olsson, J. E., and Äkerlund, M., 1983, Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases, J. Neurol. Neurosurg. Psychiatry 46: 14–17.PubMedGoogle Scholar
  95. Tanaka, M., De Kloet, E. R., De Wied, D., and Versteeg, D.H.G., 1977, Arginine-8-vasopressin affects catecholamine metabolism in specific brain nuclei, Life Sci. 20: 1799–1808.PubMedGoogle Scholar
  96. Timsit-Berthier, M., Mantanus, H., Jacques, M. C., and Legros, J. J., 1980, Utilité de la lysine-vasopressine dans le traitement de l’amnesie post-traumatique, Acta Psychiatrica Belg. 80: 728–747.Google Scholar
  97. Timsit-Berthier, M., Mantanus, H., Devos, J. E., and Spiegel, R., 1982, Action of lysine-vasopressin on human electroencephalographic activity, Neuropsychobiology 8: 248–258.PubMedGoogle Scholar
  98. Tinklenberg, J. R., Pfefferbaum, A., and Berger, P. A., 1981a, 1-Desamino-D-arginine-vasopressin in cognitively impaired patients, Psychopharmacol. Bull. 17: 206–207.Google Scholar
  99. Tinklenberg, J. R., Pigache, R., Pfefferbaum, A., and Berger, P. A., 1982, Vasopressin peptides and dementia, in: Alzheimer’s Disease. A report of Progress in Research (S. Corkin, K. I. Davis, J. H. Growdon, E. Usdin, and R. J., Wurtman, eds.), pp. 463–469, Raven, New York.Google Scholar
  100. Urban, I., and De Wied, D., 1978, Neuropeptides: Effects on paradoxical sleep and theta rhythm in rats, Pharmacol. Biochem. Behav. 8: 51–59.PubMedGoogle Scholar
  101. Van Beek-Verbeek, G., Fraenkel, H.M., and Van Ree, J.M., 1983, Des-gly9-[Arg8]-Vasopressin may facilitate methadone detoxification of heroin addicts, Subst. Alcohol Actions/Misues 4: 375–382.Google Scholar
  102. Van Wimersma Greidanus, Tj. B., Dogterom, J., and De Wied, D., 1975, Intraventricular administration of anti-vasopressin serum inhibits memory consolidation in rats, Life Sci. 16: 637–644.Google Scholar
  103. Van Wimersma Greidanus, Tj. B., Bohus, B., and De Wied, D., 1976, CNS sites of action of ACTH, MSH and vasopressin in relation to avoidance behavior, in Anatomical Neuroendocrinology (W. E. Strumpf and L. D. Grant, eds.), pp. 284–289, Karger. Basel.Google Scholar
  104. Versteeg, D. H. G., De Kloet, E. R., Van Wimersma Greidanus, Tj. B., and De Wied, D., 1979, Vasopressin modulates the activity of catecholamine containing neurones in specific brain regions, Neurosci. Lett. 11: 69–73.PubMedGoogle Scholar
  105. Vink, M., and Jolies, J., 1985, A new version of the Trail Making task as an information processing task, J. Clin. Exp. Neuropsychol. 7: 162.Google Scholar
  106. Vranckx, C. H., Minne, Ph., Benghezal, A., Moeglen, J. M., and Audibert, A., 1979, Vasopressin and schizophrenia, in: Biological Psychiatry Today (J. Obiols, C. Ballus, E. Gonzales, E. Mondus, and J. Pujol, eds.), pp. 753–758, Elsevier/North-Holland, Amsterdam.Google Scholar
  107. Waggoner, R. W., Jr., Slonim, A. E., and Armstrong, S. H., 1978, Improved psychological status of children under DDAVP therapy for central diabetes insipidus, Am. J. Psychiatry 135: 361–362.PubMedGoogle Scholar
  108. Weingartner, H., Rapoport, J. L., Buchsbaum, M. S., Bunney, W. E., Jr., Ebert, M. H., Mikkolsen, E. J., and Caine, E. D., 1980, Cognitive processes in normal and hyperactive children and their response to amphetamine treatment, J. Abnorm. Psychiol. 89: 25–37.Google Scholar
  109. Weingartner, H., Gold, P., Ballenger, J. C., Smallberg, S. A., Summers, R., Rubinow, D. R., Post, R. M., and Goodwin, F. K., 1981a, Effects of vasopressin on human memory functions, Science 211: 601–603.PubMedGoogle Scholar
  110. Weingartner, H., Kaye, W., Gold, P., Smallberg, S., Peterson, R., Gillin, J.C., and Ebert, M., 1981b, Vasopressin treatment of cognitive dysfunction in progressive dementia, Life Sci. 29: 2721–2726.PubMedGoogle Scholar
  111. Woodward, D. J., Moises, H. C., Waterhouse, B. D., Hoffer, B. J., and Freedman, R., 1979, Modulatory actions of norepinephrine in the central nervous system, Fed. Proc. 38: 2109–2116.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Jellemer Jolles
    • 1
  1. 1.Department of Neuropsychology and Psychobiology, Clinical PsychiatryState University of MaastrichtMaastrichtThe Netherlands

Personalised recommendations